ARMATA PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of -4.60% for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-25.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2019-03-25
- ARMATA PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2018 was -4.60%.
- ARMATA PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2017 was -2.40%.
- ARMATA PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2016 was -5.20%, a 118.71% decline from fiscal 2015.
- ARMATA PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2015 was 27.80%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2018-12-31 | -4.60% 10-K · filed 2019-03-25 |
| 2017-12-31 | -2.40% 10-K · filed 2019-03-25 |
| 2016-12-31 | -5.20% 10-K · filed 2018-03-14 |
| 2015-12-31 | 27.80% 10-K · filed 2017-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |